Riociguat Patent Expiration
Riociguat is used for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) to improve exercise capacity and WHO functional class, and delay clinical worsening. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Riociguat Patents
Given below is the list of patents protecting Riociguat, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Adempas | US10662188 | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | Feb 18, 2034 | Bayer Hlthcare |
Adempas | US11203593 | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate | Feb 18, 2034 | Bayer Hlthcare |
Adempas | US6743798 | Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
Jul 16, 2019
(Expired) | Bayer Hlthcare |
Adempas | US7173037 | Carbamate-substituted pyrazolopyridines | Dec 04, 2026 | Bayer Hlthcare |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳
Riociguat Generics
Several generic applications have been filed for Riociguat.
Given below is the list of companies who have filed for Riociguat generic.
1. MSN
Msn Laboratories Private Ltd has filed for 5 different strengths of generic version for Riociguat. Given below are the details of the strengths of this generic introduced by Msn.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
0.5MG | tablet | Prescription | ORAL | AB | Sep 1, 2022 |
1MG | tablet | Prescription | ORAL | AB | Sep 1, 2022 |
1.5MG | tablet | Prescription | ORAL | AB | Sep 1, 2022 |
2MG | tablet | Prescription | ORAL | AB | Sep 1, 2022 |
2.5MG | tablet | Prescription | ORAL | AB | Sep 1, 2022 |